Baseline characteristics of mycophenolate treatment episodes in analysis 2 (risk of pregnancy onset during treatment)
| Before propensity score weighting | After propensity score weighting | |||||
| Covariates | MG period (n=12 868) | REMS period (n=8069) | ASD | MG period (n=12 870) | REMS period (n=8067) | ASD |
| Age at index date (%) | ||||||
| 15–19 | 1299 (10.1) | 754 (9.4) | 0.03 | 1263 (9.7) | 790 (9.8) | 0.00 |
| 20–29 | 2866 (22.3) | 1883 (23.3) | 0.03 | 2921 (22.7) | 1835 (22.7) | 0.00 |
| 30–39 | 5036 (39.1) | 2962 (36.7) | 0.05 | 4923 (38.3) | 3088 (38.3) | 0.00 |
| 40–44 | 3667 (28.5) | 2470 (30.6) | 0.05 | 3762 (29.3) | 2353 (29.2) | 0.00 |
| Indications* (%) | ||||||
| Tissue disorders† | 5904 (45.9) | 3959 (49.1) | 0.06 | 6062 (47.1) | 3799 (47.1) | 0.00 |
| Kidney transplant | 2612 (20.3) | 1615 (20.0) | 0.01 | 2600 (20.2) | 1631 (20.2) | 0.00 |
| Other solid organ transplants | 811 (6.3) | 488 (6.0) | 0.01 | 798 (6.2) | 502 (6.2) | 0.00 |
| Skin disorders‡ | 938 (7.3) | 660 (8.2) | 0.03 | 979 (7.6) | 615 (7.6) | 0.00 |
| Nephrology disorders | 868 (6.7) | 504 (6.2) | 0.02 | 843 (6.5) | 527 (6.5) | 0.00 |
| Myasthenia gravis | 359 (2.8) | 207 (2.6) | 0.01 | 349 (2.7) | 220 (2.7) | 0.00 |
| Autoimmune hepatitis | 299 (2.3) | 183 (2.3) | 0.00 | 295 (2.3) | 184 (2.3) | 0.00 |
| Multiple sclerosis | 275 (2.1) | 117 (1.5) | 0.05 | 242 (1.9) | 153 (1.9) | 0.00 |
| Rheumatoid arthritis | 878 (6.8) | 531 (6.6) | 0.01 | 862 (6.7) | 536 (6.6) | 0.00 |
| Arteritis | 469 (3.6) | 227 (2.8) | 0.05 | 429 (3.3) | 270 (3.3) | 0.00 |
| Iridocyclitis | 263 (2.0) | 166 (2.0) | 0.00 | 265 (2.1) | 168 (2.1) | 0.00 |
| Blood disorder/bone marrow transplant | 174 (1.3) | 82 (1.0) | 0.03 | 168 (1.3) | 8 (1.1) | 0.02 |
| Neuroinflammatory disorder | 157 (1.2) | 78 (1.0) | 0.02 | 155 (1.2) | 81 (1.0) | 0.02 |
| Unknown | 1314 (10.2) | 721 (8.9) | 0.04 | 1250 (9.7) | 784 (9.7) | 0.00 |
| Recent mycophenolate treatment episode | 4153 (32.3) | 3334 (41.3) | 0.19 | 4604 (35.8) | 2886 (35.8) | 0.00 |
| Charlson Comorbidity Index (%) | ||||||
| 0–1 | 6881 (53.5) | 4397 (54.5) | 0.02 | 6931 (53.8) | 4347 (53.9) | 0.00 |
| >1 | 5987 (46.5) | 3672 (45.5) | 0.02 | 5938 (46.2) | 3720 (46.1) | 0.00 |
| Depression (%) | 1249 (9.7) | 886 (10.1) | 0.04 | 1317 (10.2) | 826 (10.2) | 0.00 |
| Baseline contraceptive use§ (%) | 1685 (13.1) | 1088 (13.5) | 0.01 | 1709 (13.3) | 1075 (13.3) | 0.00 |
| Recent pregnancy (%) | 113 (0.9) | 60 (0.7) | 0.02 | 106 (0.8) | 67 (0.8) | 0.00 |
| Use of teratogenic drugs (%) | 5784 (44.9) | 3463 (42.9) | 0.04 | 5691 (44.2) | 3571 (44.2) | 0.00 |
| Insurance holder status (%) | ||||||
| Employee | 6649 (51.7) | 3942 (48.8) | 0.06 | 6506 (50.5) | 4074 (50.5) | 0.00 |
| Spouse | 3673 (28.5) | 2258 (28.0) | 0.01 | 3640 (28.3) | 2282 (28.3) | 0.00 |
| Other dependent | 2546 (19.8) | 1869 (23.2) | 0.08 | 2723 (21.2) | 1710 (21.2) | 0.00 |
| Region of residence | ||||||
| Northeast | 1879 (14.6) | 1303 (16.1) | 0.04 | 1952 (12.2) | 1225 (15.2) | 0.00 |
| North central | 2785 (21.6) | 1578 (19.6) | 0.05 | 2680 (20.8) | 1677 (20.8) | 0.00 |
| South | 5292 (41.2) | 3230 (40.0) | 0.02 | 5241 (40.7) | 3286 (40.7) | 0.00 |
| West | 2706 (21.0) | 1756 (21.8) | 0.02 | 2744 (21.3) | 1721 (21.3) | 0.00 |
| Unknown | 206 (1.6) | 202 (2.5) | 0.06 | 252 (2.0) | 158 (2.0) | 0.00 |
*Indications are not mutually exclusive.
†Tissue disorders include systemic lupus erythematosus, sclerosis and other tissue conditions.
‡Skin disorders include psoriasis, lupus and other skin conditions.
§Contraceptive use was ascertained between 180 and 60 days before index date.
ASD, absolute standardised difference; MG, medication guide; REMS, Risk Evaluation and Mitigation Strategy.